Sleep apnea study reaches milestone
ANDOVER, Mass. – The Sleep Apnea cardioVascular Endpoints Study (SAVE) has enrolled 2,500 patients, Royal Philips, a major sponsor, announced Feb. 18. The patients are spread across seven countries, and 84 hospitals and medical institutions. The aim of the study: to determine the effects of CPAP treatment in preventing heart attack, stroke or heart failure in high-risk patients with moderate to severe obstructive sleep apnea (OSA). In addition to sponsoring the study, Philips has played an active role in training personnel at the various SAVE sites in CPAP adherence techniques.